Agios Pharmaceuticals Inc.

30.28
-0.56 (-1.82%)
At close: Mar 28, 2025, 3:59 PM
29.30
-3.25%
After-hours: Mar 28, 2025, 06:25 PM EDT

Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.

The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc. logo
Country United States
IPO Date Jul 24, 2013
Industry Biotechnology
Sector Healthcare
Employees 486
CEO Brian M. Goff M.B.A.

Contact Details

Address:
88 Sidney Street
Cambridge, Massachusetts
United States
Website https://www.agios.com

Stock Details

Ticker Symbol AGIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001439222
CUSIP Number 00847X104
ISIN Number US00847X1046
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Brian M. Goff M.B.A. Chief Executive Officer & Director
Cecilia Jones Chief Financial Officer
James William Burns Corporate Secretary & Chief Legal Officer
Dr. Craig B. Thompson M.D. Co-Founder
Dr. Lewis Clayton Cantley Ph.D. Co-Founder
Dr. Sarah Gheuens M.D., Ph.D. Chief Medical Officer and Head of Research & Development
Dr. Shin-San Su Ph.D. Co-Founder
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. Co-Founder
T. J. Washburn Vice President, Controller & Principal Accounting Officer
Tsveta Milanova Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 07, 2025 4 Filing
Mar 07, 2025 3 Filing
Mar 05, 2025 S-8 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing